AOD9604
AOD9604 is a 16-amino acid C-terminal fragment of human growth hormone (hGH residues 176–191). It selectively stimulates fat breakdown (lipolysis) and inhibits new fat formation (lipogenesis) via β3-adrenergic receptor activation, without elevating IGF-1 or causing the systemic growth-related side effects of full-length hGH, making it a targeted peptide for fat metabolism research.
AOD9604 (Advanced Obesity Drug 9604) is a synthetic 16-amino acid peptide corresponding to the conserved C-terminal lipolytic domain (residues 176–191) of human growth hormone (hGH), optimized for targeted adipose tissue metabolism research:
Core Mechanism & Key Properties
- Selectively activates β3-adrenergic receptors on adipocytes, stimulating hormone-sensitive lipase (HSL) to trigger breakdown of stored triglycerides into usable free fatty acids (lipolysis)
- Inhibits de novo lipogenesis (new fat formation) by downregulating key lipogenic enzymes including acetyl-CoA carboxylase and fatty acid synthase
- Critical distinction from full-length hGH: Does not bind to growth hormone receptors, does not elevate circulating IGF-1 levels, and does not produce the systemic anabolic, glycemic, or growth-related side effects of full hGH administration
- Preferentially mobilizes visceral and stubborn abdominal adipose tissue in preclinical models
Primary Research Applications
- Obesity and adipose tissue metabolism research
- Targeted lipolysis and body composition modulation studies
- Investigations of selective fat reduction without systemic growth hormone-related effects
- Preclinical models of metabolic syndrome and visceral adiposity
Manufactured to ≥98% purity, sterile-filtered, and lyophilized for long-term storage stability.
For laboratory research use only; not intended for human or veterinary administration.
Request Quote / COA
By submitting this form, you confirm the product is intended for laboratory research use only.
